Clinical Trial Update: Clarithromycin as Immunomodulator for the Management of Sepsis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating clarithromycin as an immunomodulator for sepsis (including severe sepsis and septic shock) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sepsis
• Septic Shock

Drugs mentioned

• Biaxin (clarithromycin)
• clarithromycin (clarithromycin)

Snippet

Sponsor: University of Athens | Conditions: Sepsis, Severe Sepsis | Phase 3 | Status: COMPLETED